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A B S T R A C T   
Cardiovascular disease (CVD) is a general term for conditions which are the leading cause of death in the world. 
Quick restoration of tissue perfusion is a key factor to combat these diseases and improve the quality and 
duration of patients' life. Revascularization techniques include angioplasty, placement of a stent, or surgical 
bypass grafting. For the latter technique, autologous vessels remain the best clinical option; however, many 
patients lack suitable autogenous due to previous operations and they are often unsuitable. Therefore, synthetic 
vascular grafts providing antithrombosis, neointimal hyperplasia inhibition and fast endothelialization are still 
needed. To address these limitations, 3D printed dipyridamole (DIP) loaded biodegradable vascular grafts were 
developed. Polycaprolactone (PCL) and DIP were successfully mixed without solvents and then vascular grafts 
were 3D printed. A mixture of high and low molecular weight PCL was used to better ensure the integration of 
DIP, which would offer the biological functions required above. Moreover, 3D printing technology provides the 
ability to fabricate structures of precise geometries from a 3D model, enabling to customize the vascular grafts' 
shape or size. The produced vascular grafts were fully characterized through multiple techniques and the last step 
was to evaluate their drug release, antiplatelet effect and cytocompatibility. The results suggested that DIP was 
properly mixed and integrated within the PCL matrix. Moreover, these materials can provide a sustained and 
linear drug release without any obvious burst release, or any faster initial release rates for 30 days. Compared to 
PCL alone, a clear reduced platelet deposition in all the DIP-loaded vascular grafts was evidenced. The hemolysis 
percentage of both materials PCL alone and PCL containing 20% DIP were lower than 4%. Moreover, PCL and 
20% DIP loaded grafts were able to provide a supportive environment for cellular attachment, viability, and 
growth.   
1. Introduction 
Cardiovascular disease (CVD) is a general term used for conditions 
affecting the heart or blood vessels. The main types of CVDs include 
ischemic heart disease, heart failure, peripheral arterial disease and 
stroke [1]. CVDs remain the leading causes of death globally and 
represent a main contributor to reduced quality of life [2,3]. For 
instance, it has been estimated that 17.9 million peopled died from CVDs 
in 2016, representing 31% of all global deaths, and this burden is pre-
dicted to increase to 23.6 million death globally by 2030 [4,5]. Quick 
restoration of tissue perfusion is a key factor to prevent heart failures in 
people suffering from coronary heart disease and for supporting the 
repair of ischemic limbs. Revascularization techniques include angio-
plasty, placement of a stent, or surgical bypass grafting [6]. For the latter 
technique, autologous vessels remain the best clinical option, but the 
process of harvesting vessels is invasive, and they are often unsuitable 
[7–9]. Therefore, synthetic vascular grafts made from biocompatible 
materials are still needed [1,6]. 
These artificial vascular grafts offer advantages of flexibility in their 
shape, length, and diameter, which can be used in distinct practical 
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settings [10,11]. Moreover, most of these are made from non- 
biodegradable materials, such as expanded polytetrafluoroethylene, 
polyethylene terephthalate and polyurethane [1,12]. Although these 
polymers are exceptional in their biocompatibility, chemical stability, 
low toxicity and long-term robustness, have a limited success when used 
for the replacement of small-diameter blood vessels (<6 mm internal 
diameter) [13,14] due to the unfavorable biological responses, 
including the formation of thrombosis, neointimal hyperplasia and 
delayed reendothelialization [15–17]. 
Attempts to overcome the limitations of these synthetic polymer 
grafts include embed them with antithrombotic drugs, vascular tissue 
engineering [7] or the development of new combinations of materials 
that promote the healing process and facilitate gradual degradation and 
complete replacement by natural blood vessels [12]. In this regard, 
polycaprolactone (PCL) is a biodegradable and hydrophobic synthetic 
polymer, which has been extensively used for cardiovascular applica-
tions due to its non-toxicity and biocompatibility, among other features 
[12,18–20]. Vascular grafts made from biodegradable polymers have 
the potential to regenerate blood vessels similar to those of patients and 
can be degraded, thus enabling a functional vascular replacement 
[21–23]. Moreover, this polymer presents a slow bioresorption kinetic 
(>1 year), which makes it a promising candidate for the development of 
tissue-engineered blood vessels, enabling seeded cells to produce 
extracellular matrix (ECM) and maintain a sustained drug release 
[19,20,24,25]. PCL has also been approved by the Food and Drug 
Administration (FDA) for its use as implantable biomaterial as well as in 
the development of drug delivery systems [26]. 
The combination of vascular grafts with antithrombotic drugs is a 
simple way to improve the biological functions of biodegradable poly-
mers [1,19,21,27,28]. An ideal vascular graft should be able to prevent 
thrombosis and intimal hyperplasia, as well as promoting rapid endo-
thelialization [21]. Although different antithrombotic drugs could be 
used for this purpose, dipyridamole (DIP), a clinically used drug for 
different cardiovascular conditions, has shown promising results 
reducing smooth muscle cell (SMC) proliferation [29–31] and promot-
ing proliferation of vascular endothelial cells (EC) [31,32] in addition to 
its antithrombotic effect [33]. Different techniques including electro-
spinning [19,21,34] or thermally induced phase separation [35], among 
others, can be used to fabricate vascular grafts containing pharmaceu-
tically active compounds. Alternatively, additive manufacturing (AM) 
can be used not only to prepare tailored vascular grafts personalized to 
the patient, but to include antithrombotic compounds to prevent the 
thrombosis associated with valvular prosthesis and vascular grafts [1]. 
AM, also known as 3D printing, is an increasingly growing 
manufacturing technology that provides the ability to fabricate struc-
tures of precise geometries from 3D model by the deposition of material 
in a layer-by-layer fashion. This technology has been previously inves-
tigated for the manufacture of multiple 3D devices medical devices 
including surgical meshes [36–38], subcutaneous Implants [39], wound 
dressings [40,41] or catheters [42,43] among others, showcasing the 
versatility of this technique for biomedical applications. In addition, 
cardiovascular prosthesis containing a small percentage of antimicrobial 
compounds to prevent infections have been performed using 3D printing 
technology [1]. The 3D printing approach can be used to produce 
biodegradable, biocompatible implantable devices in an easy and 
affordable manner [39,44,45]. 
The aim of this work is to develop 3D printed PCL-based vascular 
grafts loaded with DIP. The resulting vascular grafts were characterized 
using different techniques such as such as Fourier-transform infrared 
(FTIR) spectroscopy, scanning electron microscopy (SEM), differential 
Scanning Calorimetry (DSC), thermogravimetric analysis (TGA) and X- 
ray micro-computed tomography. Moreover, the grafts were evaluated 
by analysing their drug release, antiplatelet effect, hemocompatibility 
and cytocompatibility. 
2. Material and methods 
2.1. Materials 
Two different PCL, high molecular weight PCL (CAPA™ 6506, MW 
= 50,000 g/mol), henceforth referred to as H-PCL, and low molecular 
weight PCL (CAPA™ 2054, MW = 550 g/mol), henceforth referred to as 
L-PCL were donated by Perstorp (Malmö, Sweden). DIP was purchased 
from Tokyo Chemical Industry UK Ltd. (Oxford, UK). Rabbit blood in 
sodium citrate was provided from Rockland (Reading, UK). Ethanol was 
provided by Sigma-Aldrich (Dorset, UK). Glutaraldehyde 25% EM Grade 
was obtained from Agar Scientific Ltd. (Essex, UK). Phosphate buffer 
solution (PBS) was obtained from VWR Chemicals (Ohio, USA). All 
materials and reagents were used as received. 
2.2. Vascular graft design and manufacture 
After a variety of preliminary formulation tests (data not shown), a 
mixture of H-PCL/L-PCL 60%/40% w/w was selected to prepare the 
different vascular grafts. The PCL mixture was combined with different 
concentrations of DIP (5%, 10% and 20%) (Table 1) by using the 
SpeedMixer™ DAC 150.1 FVZ-K (Hauschild GmbH & Co. KG, Westfalen, 
Germany) at 3000 rpm for 3 min. Then, the mixture was added into a 
metal mold (Fig. 1) and placed in the oven at 60 ◦C for 30 min. Imme-
diately after that, a metal bar was used to create the lumen of the grafts 
(Fig. 1A). Finally, the molded grafts were taken out when the metal mold 
was cooled down at room temperature. 
2.2.1. 3D printing grafts 
Two of the previous formulations used for the molded grafts, blank 
PCL and 20% DIP were also prepared to 3D print vascular grafts. As 
previously stated, samples were mixed using the SpeedMixer™ DAC 
150.1 FVZ-K at 3000 rpm for 3 min prior to the 3D-printing process. 
Then, the mixture was placed into the metal syringe of the 3D bioprinter 
at 60 ◦C for 30 min before printing. The grafts were designed using a 
computer-aided design (CAD) software and printed using a 3D bio-
printer (Bioscaffolder 3.2, GeSiM) (Radeberg, Germany). The 3D Bio-
Scaffolder system was equipped with two interchangeable nozzles (0.5 
and 0.3 mm). The larger nozzle was used to print objects used during 
physicho-chemical characterization of the materials. On the other hand, 
grafts printed for microscopy and computer assisted tomography eval-
uation were printed using the 0.3 mm nozzle. The print speed was 10 
mm/s, the print temperature used was 60 ◦C and the layer height was 
0.35 mm. Finally, these grafts were printed longitudinally as can be seen 
in Fig. 1B. All layers were aligned in the same direction. 
2.3. Grafts characterization 
The morphology of the designed grafts was evaluated by using 
scanning electronic microscopy (SEM) (Hitachi TM3030; Tokyo, Japan) 
and a Leica EZ4 D digital microscope (Leica, Wetzlar, Germany). The 
digital microscope was equipped with NIGHTSEA Model SFA Stereo-
microscope Fluorescence Adapter with the Royal Blue excitation/emis-
sion to obtain fluorescence images. To investigate microstructural 
features of the implants, X-ray microcomputed tomography was per-
formed using a Bruker Skyscan 1275 with Hamamatsu L11871 source at 
Table 1 
Molded grafts formulations.  
Formulations PCL mixture (%) 
H-PCL (60%)/L-PCL (40%) 
DIP (%) 
Blank PCL  100 – 
5% DIP  95 5 
10% DIP  90 10 
20% DIP  80 20  
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80 kV and 87 μA. Volumetric reconstruction was performed using 
Bruker CTvol software, where attenuation thresholding was carried out 
manually to eliminate speckle around the samples. FTIR spectra of the 
resulting molded and 3D printing grafts were recorded using a Spectrum 
Two instrument (Perkin Elmer, Waltham, MA) by the attenuated total 
reflectance (ATR) technique. The spectra were recorded from 4000 to 
600 cm− 1 with a resolution of 4 cm− 1 and a total of 32 scans were 
collected. 
The thermal properties of the grafts were evaluated. As the material 
was subjected to moderate temperatures (60 ◦C) during the different 
manufacturing processes, the thermal behavior of the polymer mixtures 
with and without DIP were examined. For this purpose, a thermogra-
vimetric analysis (TGA) was performed to measure the weight loss of the 
molded grafts and the 3D printed grafts. Small pieces of these grafts 
between 3 and 10 mg were used for this analysis. TGA was performed 
using a Q500 Thermogravimetric analysis (TA instruments, Bellingham, 
WA, USA). Scans were run from room temperature to 400 ◦C, at the 
heating rate of 30 ◦C/min under a nitrogen flow rate of 50 mL/min. 
Moreover, A Q100 differential scanning calorimeter (DSC) (TA in-
struments, Bellingham, USA) was used to establish if the drug was 
crystalline or amorphous within the resulting grafts. For this purpose, 
the drug powder and again small pieces of the grafts were examined. 
Scans were run from 30 ◦C to 200 ◦C at 10 ◦C/min under a nitrogen flow 
rate of 50 mL/min. 
2.4. Platelet adhesion study 
Blood platelet deposition on the grafts surface was measured using 
rabbit platelet-rich plasma (PRP), which was produced by centrifuging 
the rabbit blood in sodium citrate (Rockland Immunochemicals, Inc.; 
Pottstown, USA) at 1840 rpm for 15 min [46]. Small pieces of 1 mm 
were obtained from the different molded (Blank PCL and 5, 10 and 20% 
DIP) and 3D printed grafts (Blank PCL and 20% DIP) and placed in 96- 
well plate. A 200 μL aliquot of the PRP was poured on the sample surface 
in the 96-well plate. Samples were then incubated at 37 ◦C for 2 h. After 
this incubation step, samples were washed three times using PBS in 
order to remove the non-adherent platelets. Further, a 2.5% glutaral-
dehyde solution was used to fix the PRP-treated samples for 2 h. After 
washing three times with PBS, a series of ethanol solutions (70% for 15 
min and 100% for 24 h) were used to dehydrate the samples. Finally, the 
adhered blood platelets on the grafts surface were observed by using 
SEM (Hitachi TM3030; Tokyo, Japan). 
2.5. In vitro drug release studies 
A release study was performed to calculate the amount of DIP eluting 
from the resulting molded grafts. For this end, molded grafts of 5 mm in 
length containing DIP (5%, 10% and 20%) were weighted and placed in 
vials containing 25 mL of PBS to maintain Sink conditions. Subse-
quently, these vials were located in a shaking incubator at 37 ◦C at 40 
rpm. At specific time points (each 24 h), the samples were removed from 
the vials, dried, and transferred to new vials containing 25 mL of fresh 
PBS. The concentration of DIP was quantified using fluorescence spec-
troscopy (FLUOstar Omega Microplate Reader, BMG LABTECH, Orten-
berg, Germany). For this purpose, the collected release medium was 
diluted 1:1 in 100% ethanol (as performed in the calibration curve). The 
fluorescence intensity was then measured at 280 nm (excitation wave-
length) and 460 nm (emission wavelength) [1,21]. 
2.6. Mechanical testing 
Mechanical testing was carried out to evaluate mechanical properties 
of 3D-printed blank PCL samples and samples containing 20% of DIP. 
For this purpose, 1 × 0.7 × 7 cm strips were printed using the same 
conditions described in Section 2.2.1. and a 0.5 mm nozzle. These strips 
were printed longitudinally in the same way than the vascular grafts. 
Mechanical properties were measured using a TA.XTplus texture ana-
lyser (Stable Micro Systems, Surrey, UK). Each strip was fixed vertically 
using two clamps separated 4 cm and stretched at a rate of 10.2 mm/ 
min. Force displacement curves were recorded and different parameters 
were calculated from these curves. The elastic modulus was obtained as 
the slope of the initial linear section of the stress/strain curve [47]. 
Moreover, peak stress and strain were measured as ultimate tensile 
strength and strain at failure respectively [47]. 
2.7. Hemocompatibility study 
Hemolysis was evaluated by determining the relative amount of 
hemoglobin released from red blood cells (RBCs) in rabbit blood in so-
dium citrate (Rockland Immunochemicals, Inc.; Pottstown, USA) 
exposed to the 3D printed constructs [1,48]. Initially, 1 mL of blood was 
poured into a 1.5 mL Eppendorf tube, which was centrifuged at 2000g 
for 5 min. The supernatant was discarded, and the resulting pellet was 
resuspended in 1 mL of a saline solution (0.9% NaCl solution). The 
whole process was repeated 3 times. Finally, the resuspended pellet in 1 
mL of saline solution or distilled water (for the positive control) was 
transferred to a vial containing 9 mL of saline solution or water, 
respectively. A piece of the 3D printed constructs (weighting between 23 
and 32 mg) was placed in a 1.5 mL Eppendorf tube for the hemolytic 
evaluation. Next, 200 μL of the previous diluted blood solution was 
added to the tube. After 1 h incubation at 37 ◦C, the tubes were 
centrifuged at 2000 g for 5 min. Then, the supernatant was carefully 
pipetted out and transferred into a 96-well plate to measure the absor-
bance at 545 nm using and UV/vis spectrometer (FLUOstar Omega 
Microplate Reader, BMG LABTECH, Ortenberg, Germany) [21,49]. The 
absorbance at 545 nm of the diluted blood with distilled water or saline 
Fig. 1. Diagram showing how vascular grafts were prepared using a metal mold (A). Diagram illustrating the 3D printing process (B).  
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solution to make positive and negative controls, respectively, was also 
measured. Finally, the percentage of hemolysis or hemolysis ratio was 
calculated by Eq. (1). 
Hemolysis (%) = 100×TS − NC/PC − NC (1)  
where TS is the absorbance value of the test sample, and NC and PC are 
the absorbance values of negative and positive controls. 
2.8. HUVECs growth 
3D printed grafts were sterilised under UV irradiation for a total of 1 
h and briefly calibrated with warm cell culture medium (EGM-2 media 
(LONZA 00190860)). To evaluate cellular accommodation and growth, 
sterilised grafts were placed in a 24 well low-attachment surface culture 
plate. A total of 500,000 human umbilical vein endothelial cells 
(HUVECs) (ATCC CRL-1730) were suspended in 500 μL of EGM-2 media 
and distributed on the top of each graft. The prepared plate was briefly 
swirled to allow even distribution of the cells in each well before being 
placed in the incubator. Cells were allowed to attach for a total of 24 h 
before being supplemented with fresh cell medium. Thereafter cells 
were cultured for an additional 48 h to assess graft biocompatibility. 
Cellular attachment was assessed through phase contrast light micro-
scopy, whilst cellular viability and proliferation was assessed through 
the use of the CyQUANT™ NF Cell Proliferation Assay (Thermo Fisher 
Scientific, C35006). Before the performance of the cell proliferation 
assay, each graft was carefully transferred to a new well. 
2.9. Statistical analysis 
All quantitative data were expressed as a mean ± standard deviation. 
Statistical analysis was performed using a one-way analysis of variance 
by ANOVA with Tukey's post-hoc. For the cell proliferation experiments 
and mechanical testing an unpaired two-tailed t-test was used. A sta-
tistical level of p < 0.05 was considered to be statistically significant. 
3. Results and discussion 
3.1. Preparation and characterization of PCL-based vascular grafts 
containing DIP 
Cylindrical grafts with a diameter of 6 mm containing different DIP 
concentrations were manufactured using metal mold and 3D printing 
technology. The molded grafts were prepared to do a preliminary 
evaluation of the PCL-based materials loaded with DIP. Subsequently, 
3D printing was used to prepare vascular grafts using the higher DIP 
concentration (20% w/w) as preliminary work on DIP loaded materials 
suggested that higher DIP loadings ranging between 15 and 20% pro-
vided the best antiplatelet effect [21]. Additionally, blank grafts were 
prepared using 3D printing. The yellow color of the grafts darkened as 
the amount of DIP added increased, confirming that an increased 
amount of DIP is present in the performed grafts (Fig. 2A). It can be 
inferred that the drug was mixed successfully with the PCL matrix. This 
can be corroborated by microscopy (Fig. 2B–F) which shows the drug 
compound (DIP) was dissolved within the PCL matrix, as the vascular 
grafts and their cross sections were completely homogeneous, showing 
no visible DIP aggregates. Thus, it is indicating that the mixing process, a 
dual asymmetric centrifugal laboratory mixer system, was successfully 
performed. The good miscibility between PCL and DIP can be explained 
by their chemical structures. Interactions between the PCL matrix and 
DIP, possibly through hydrogen bonding due to the hydroxyl groups, 
which are present in the DIP molecule, may be influencing the mixing 
process [21,33]. 
The good miscibility between PCL and DIP was also evaluated by 
using SEM. SEM images of the vascular grafts are shown in Fig. 3 and no 
visible DIP crystals or aggregates were observed in their surfaces or cross 
sections. Moreover, the surface and the cross section of the blank sam-
ples were quite homogeneous indicating both H-PCL and L-PCL were 
successfully mixed. Although no visible DIP crystals were found, the 
surface of the vascular grafts became rough after increasing DIP per-
centage. As reported in the literature, drug concentration can affect the 
surface morphology of the final device [21,50]. 
The use of L-PCL in combination with H-PCL may increase the rate of 
degradation of the produced implantable devices, as previously reported 
by Stewart et al. [51]. In fact, degradation time of PCL is dependent on 
its molecular weight [24]. Higher molecular weight results in a greater 
number of ester bonds that need to be cleaved [24]. Moreover, L-PCL 
allowed a better DIP integration within the thermoplastic matrix 
without using any solvents as required by using electrospinning process. 
This type of solvents can be harmful to humans, particularly when using 
for implantable devices such as vascular grafts [1]. In addition, elec-
trospinning technique is more complicated to use and control in com-
parison with 3D printing techniques. Moreover, one the advantage of 
this emerging technology is that surgeons can easily design a vascular 
Fig. 2. Molded grafts containing no DIP, 5%, 10% and 20% DIP (left to right) (A). Cross section image of the 20% DIP molded graft (B). 3D printed graft containing 
20% DIP (C) and its cross section (D). 3D printed graft containing no DIP (E) and its cross section (F). Scale bar panel B: 2 mm. Scale bars panels C–F: 1 mm. 
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graft on demand, with modifications in the shape, size and dose, 
allowing the device to be personalized to the individual needs of each 
patient [52–55]. These modifications will be more complicated when 
using electrospinning process. 
The 3D printed vascular grafts were analysed using a Bruker Skyscan 
1275 μCT system in order to investigate their architecture and distri-
bution of drug. Both types of samples were characterized by a homog-
enous and defect-free structure and the presence of DIP did not alter 
their morphology. As reported in Fig. 4A–F, volumetric reconstructions 
showed no differences between blank PCL and 20% DIP-loaded vascular 
grafts. This is most likely due to the similar density values of the poly-
meric material and drug used, which are both around (1 g/cm3). These 
results indicate that the grafts were well printed and did not present any 
defects in the graft walls. PCL layers of material were fused together as 
the printing temperature was higher than PCL melting temperature. 
Additionally, Fig. 4G shows the dimensions of the 3D printed vascular 
grafts. These results suggest that the resulting 3D printed grafts pre-
sented lumen dimensions ca. 2 mm of lumen. These results show that 3D 
printing can be used for the production of small diameter vascular grafts 
(<6 mm internal diameter) [13,14]. When comparing the dimensions 
described in Fig. 4G for blank vascular grafts and 20% DIP vascular 
grafts it was seen that the only dimension that was significantly different 
was LV. Blank PCL showed a slightly larger values for this dimension. 
This can be due to the printing process as the grafts were produced by 
adding layers of materials along that axis. This can be easily corrected 
when printing by correcting distance between the plate and the nozzle 
before printing. 
The obtained FTIR spectra of the different vascular graft formula-
tions and DIP crystalline powder are presented in the Fig. 5. The spectra 
of the blank vascular grafts exhibited characteristic peaks at 2943 cm− 1, 
2869 cm− 1 and 1725 cm− 1 that can be assigned to the –CH3 asymmetric 
stretching, –CH3 symmetric stretching and –C–O stretching, respec-
tively, as has been previously reported [56,57]. Furthermore, the FTIR 
spectrum of the powder drug revealed characteristic peaks, among 
others, at 2921 cm− 1 and at 1530 cm− 1 that can be attributed to the 
–CH3 asymmetric stretching and –C–N, stretching, respectively [56]. 
FTIR spectroscopy corroborated that higher amount of DIP is present in 
the vascular grafts when amount of drug added increased. In the Fig. 5A 
can be observed that the relative intensity of these DIP characteristic 
peaks increased in the different DIP-containing formulations when the 
DIP content was increased. Moreover, these peaks were not seen in the 
blank formulation. Interestingly, the carbonyl peak of PCL shifts to 
higher wavenumbers when DIP loading increases (Fig. 5C–D). More-
over, the peak width increases with DIP concentration (Fig. 5C). These 
results suggest an increase of the amorphous PCL fraction. DIP molecules 
will be located in between PCL chains reducing the crystallinity of the 
material. As expected, the same behavior was observed in the 3D printed 
grafts when DIP was added to the formulation (Fig. 5B). 
Thermal analysis was performed to establish if there were any in-
teractions between PCL and DIP, as previously stated. TGA analysis 
showed that when DIP was incorporated to the PCL-based matrix, the 
thermal behavior of the resulting materials was different than the one 
observed for the original PCL-based materials. For both, molded and 3D 
printed grafts, the Tonset of the PCL was shifted to a lower Tonset, when 
20% of DIP as added (Fig. 6A and C). To further investigate these in-
teractions between PCL and DIP, DSC analysis was also performed 
(Fig. 6B and D). The DIP DSC curve showed a sharp endothermic melting 
point at around 167.5 ◦C. This peak was not observed in the PCL-based 
vascular grafts containing DIP suggesting that the drug is interacting 
within the PCL matrix and thus it is not forming crystals. Similar results 
have been reported for other types of drugs such as curcumin [58,59]. 
These results are consistent with the FTIR results suggesting that DIP is 
interacting with PCL altering the polymer matrix crystallinity. There-
fore, these results obtained from thermal analysis are also confirming 
the previously stated interactions between PCL and DIP. 
Fig. 3. SEM images of the molded grafts containing different DIP concentrations (A–D). SEM images of the 3D printing grafts containing no DIP (E and F) and its 
cross section (G). Scale bars: 200 μm, 50 μm and 2 mm respectively. SEM images of the 3D printing grafts containing 20% DIP (H and I) and its cross section (J). Scale 
bars: 200 μm, 50 μm and 2 mm respectively. 
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3.2. Platelet adhesion experiment 
It is well known that when blood comes into contact with a foreign 
material surface, platelets play a key role in the initiation and propa-
gation of the coagulation cascade, that could lead to the formation of a 
fibrin clot [19,60]. Therefore, rabbit PRP was used to measure the 
platelet adhesion on the vascular grafts surface. The results revealed a 
clear decreased platelet deposition in all the DIP-loaded vascular grafts 
with respect to the one manufactured from PCL without the drug 
(Fig. 7). As expected, the molded vascular grafts containing 20% DIP 
showed the highest reduction in the number of adhered platelets to the 
material surface (87.89%) followed by the vascular grafts containing 
10% and 5% DIP (71.51% and 52.60%, respectively) (Fig. 7A). Signifi-
cant difference was found between the blank and DIP-loaded vascular 
grafts. The same results were found in the 3D printed vascular grafts 
(Fig. 7B). The molded and 3D printed vascular grafts containing 20% 
DIP showed virtually the same reduction in the number of adhered 
platelets, 87.89% and 87.67%, respectively, with respect to the PCL 
grafts (p > 0.05). The number of deposited platelet/mm2 is also showed 
in Fig. 7C and D. The reduction in the number of adhered platelets in our 
DIP-loaded vascular grafts are in line or even better than the ones found 
using aspirin or DIP-loaded electrospun scaffolds made from PCL or 
biodegradable elastic poly(urethane), respectively [19,21]. These re-
sults confirm that the 3D printed material showed equivalent behavior 
to the molded grafts containing 20% (w/w) of DIP. Additionally, the 
results confirm that the selected DIP loading for the 3D printed grafts 
was appropriate as it provided the best results in terms of platelet 
adhesion. Accordingly, this drug loading was selected for subsequent 
experiments. However, before evaluating the biocompatibility of the 3D 
printed vascular grafts, DIP release over time was measured to evaluate 
the potential DIP release over the antiplatelet activity. 
3.3. In vitro drug release 
In order to ascertain the mechanism of the antiplatelet activity of the 
materials, DIP release studies were studied for 30 days. This experiment 
was designed to ascertain if samples containing higher DIP loadings 
presented a higher drug release to explain the antiplatelet activity. DIP 
release profiles from DIP-loaded vascular grafts in PBS are shown in 
Fig. 8. DIP loaded vascular grafts showed a sustained and linear drug 
release for 30 days without any obvious burst release, or any faster 
initial release rates for 30 days. Similar results have been reported by 
Punnakitikashem et al. using DIP loaded nanofibrous scaffolds [21]. 
However, in this work, the authors obtained release curves showing two 
clear regions: a first phase with a quicker release during the first 3 days 
followed by a second slower linear phase. It could be explained by the 
fact that the solved DIP in the polymer solution had more predisposition 
to migrate close to the electrospun fibers surface during the electro-
spinning process, as previously reported for metronidazole benzoate and 
PCL electrospun nanofibers [61]. Furthermore, the release profile can be 
controlled by the amount of added DIP to the vascular grafts. As ex-
pected, the vascular grafts containing 20% DIP showed the higher drug 
release (1341.83 μg) followed by the vascular grafts containing 10% and 
5% DIP (1172.00 and 1012.86 μg, respectively) (Fig. 8A). On the other 
hand, when the release is expressed as percentage of the initial DIP 
loading, the vascular grafts containing 5% DIP showed a higher 
Fig. 4. Characterization of the 3D printed blank PCL (A, B, C) and 20% DIP-loaded (D, E, F) vascular grafts through μCT analysis. Representative images of the 3D 
volume reconstruction (A, D), x-y cross section (B, E) and inner topology (C, F); scale bar = 2 mm. Table showing the dimensions of the 3D printed vascular grafts and 
the cross-section diagram with legend for these dimensions (G). 
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Fig. 5. FTIR spectra of the molded (A) and 3D printed grafts (B). Magnification of the carbonyl peak for the molded (C) and 3D printed grafts (D).  
Fig. 6. TGA (A) and DSC (B) curves of molded grafts and TGA (C) and DSC (D) curves of the 3D printed grafts.  
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percentage released (14.03%), followed by the vascular grafts contain-
ing 10% and 20% DIP (7.30 and 3.85%, respectively) (Fig. 8B). There-
fore, these results also support the previous described interaction 
between the PCL matrix and DIP. The same behavior has also been re-
ported using a different polymer matrix, thermoplastic polyurethane 
(TPU), with DIP [1], or other drug compounds, such as levofloxacin and 
17-β-estradiol [36,37]. 
It is important to note that materials containing higher DIP loadings 
showed a more effective antiplatelet activity. The DIP release results 
suggest that during the initial stages of the release experiments the 
resulting materials containing different DIP loadings showed similar 
release profiles in terms of amount of DIP released. However, the anti-
platelet activity reported in Fig. 7 suggest that these 3 types of materials 
have an antiplatelet activity proportional to DIP loading. These results 
suggest that the antiplatelet activity of the material is correlated to the 
DIP loading into the material rather than to the DIP released. Accord-
ingly, these results suggest that in order to achieve good antiplatelet 
activity the drug should remain in the surface of the material rather than 
been released. In this way, 20% seem to be the best option not only for 
the previously reported antiplatelet activity but for its slower release. 
Fig. 8B shows that materials containing 20% DIP showed slower drug 
release over a period of 1 month. Accordingly, grafts prepared using this 
particular drug loading will maintain their antiplatelet activity for 
prolonged periods. 
It is important to note that DIP release will take place over all the 
surface of the graft. In order to prevent the release of DIP from the outer 
surface of the material, core-shell grafts can be manufactured. For this 
purpose a 3D printer equipment equipped with 2 extruders/nozzles can 
be used [1]. Fig. 8C shows the cross section of this type of implants that 
have been prepared using a 2-nozzle configuration for this 3D printer. 
Fluorescence microscopy image shows that DIP is located in the inner 
part of the graft whilst pure PCL is coating the graft. 
3.4. Mechanical properties of 3D printed vascular grafts 
As discussed in previous sections, grafts loaded with 20% of DIP 
presented the optimal properties in terms of antiplatelet activity and 
drug release. Therefore, this type of 3D printed vascular grafts were 
selected for further investigation. Mechanical properties of the selected 
3D printed materials were measured. Fig. 9A shows representative ex-
amples of the stress/strain curves obtained for samples containing 0 and 
20% (w/w) of DIP. The elastic modulus, ultimate tensile strength and 
strain at failure were measured (Fig. 9B–D). Blank PCL samples are 
prepared combining two PCLs with different molecular weights. The 
elastic modulus of the resulting material is lower than the elastic 
modulus reported for the high molecular weight PCL alone (93.4 vs. 
363.4 MPa) [62]. Accordingly, it can be stablished that low molecular 
weight PCL acts as a plasticiser. Moreover, the results suggest that 
incorporating DIP into the sample has a direct influence on the me-
chanical properties of the resulting material. The results obtained for the 
young modulus indicated that blank samples were stiffer than samples 
containing 20% DIP (p < 0.05). DIP improve the elasticity of the ma-
terial in the elastic region. This indicates that the drug is interacting with 
the PCL matrix as suggested in previous sections. However, the presence 
of DIP affects the plastic behavior of the polymer leading to lower ul-
timate tensile strengths and strains at failure (p < 0.05). Both types of 
materials presented higher elastic modulus than native blood vessels 
(0.3–1.5 MPa) [63]. However, these values are lower than the elastic 
modulus of the materials currently used to prepare synthetic vascular 
grafts such as: poly(tetrafluoroethylene) (500 MPa) [64] or poly 
(ethylene terephthalate) (Dacron) (14,000 MPa) [63,64]. Moreover, the 
elastic modulus of these PCL-based materials are lower than other 
biodegradable polymers used to prepare vascular grafts: poly(lactic 
acid) (1000–4000 MPa) or poly(glycolic acid) (7000–10,000 MPa). The 
elastic modulus of the materials described here are in line with the ones 
Fig. 7. Percentage of rabbit blood platelet depositions on the molded (A) and 3D printed (B) vascular grafts surface; and quantification of rabbit blood platelet 
depositions on the molded vascular grafts surface (C). SEM images of rabbit blood platelet depositions on the surfaces of the molded vascular grafts (D). 
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reported for poly(lactic-co-glycolic acid) (40–135 MPa) [63]. On the 
other hand the ultimate tensile strength is not as high as the one ob-
tained for poly(tetrafluoroethylene) (14 MPa) or poly(ethylene tere-
phthalate) (170–180 MPa) [63]. However, the obtained values are in 
line with the majority of native blood vessels (1.4–11.1 MPa) or other 
materials such as poly(lactic-co-glycolic acid) [63]. Finally, the ultimate 
tensile strength of the materials is superior to the one reported for native 
blood vessels (17–105%) [64]. 
3.5. Hemolytic evaluation 
The next step after characterizing the grafts was to evaluate the 
hemocompatibility of the resulting grafts. This test is important, as 
vascular grafts are medical devices that are going to be in direct contact 
with blood. For this test both 3D printed grafts (Blank PCL and 20% DIP) 
were evaluated. The hemolysis percentage of both were lower than 4% 
(Fig. 10). Although the vascular grafts containing 20% DIP showed a 
higher hemolysis percentage, there was no significance difference with 
respect to the blank PCL (p > 0.05). Samples displaying a hemolysis 
percentage lower than 5% have been defined as hemocompatible 
[65,66]. 
3.6. In vitro HUVECs growth 
The biocompatibility of each 3D printed vascular graft (Blank PCL 
and 20% DIP) was investigated through culturing HUVECs onto UV- 
sterilised grafts for a total of 72 h and assessing cell viability and pro-
liferation. Following an incubation period of 24 h, cells were found to 
readily attach to each graft. Evaluation 24 h post the incubation period 
through phase contrast microscopy, as can be seen in Fig. 11A, 
confirmed the HUVECs to have formed a monolayer on each graft type. 
Further analysis 48 h post incubation displayed each graft type to host 
an even greater number of cells compared to 24 h, as was supported by 
the CyQUANT NF cell proliferation assay (Fig. 11B) (p > 0.05). How-
ever, whilst the cell proliferation assay did not detect a significant dif-
ference between the two grafts at the 24-h time point, a statistically 
significant increase in growth was observed between the two grafts at 
the 48-h timepoint, suggesting the cells to proliferate more readily on 
the control graft. Nevertheless, each graft was able to provide a suitable 
milieu to stimulate a significant increase in cell growth between the two 
time points. Overall, this data collectively indicates the ability of the 
20% DIP loaded grafts to provide a supportive environment for cellular 
attachment, viability, and growth. 
4. Conclusions 
Biodegradable PCL-based vascular grafts loaded with DIP were suc-
cessfully manufactured using 3D printing technology. DIP was selected 
as a drug candidate due mainly to its antithrombotic effect. DIP was 
properly mixed within the PCL matrix, which was confirmed by SEM. 
This good miscibility can be attributed to the hydrogen bonding be-
tween the drug and the polymer matrix. Moreover, the results of the 
thermal analysis are also corroborating an interaction between DIP and 
the PCL matrix. DIP-loaded grafts are capable of providing a sustained 
and linear drug release without any obvious burst release, or any faster 
initial release rates for 30 days. These results could be explained by the 
Fig. 8. DIP release expressed in μg as a function of time for the different DIP loaded grafts (A). DIP release expressed in percentage as a function of initial DIP drug 
loading (B) (n = 4). Microscopy image of the cross-section of a core shell implant prepared with 20% DIP in the core and PCL 25 kDa in the shell (C). The graph was 
printed using 2 extruders from the BioScaffolder equipment: 20% DIP core was printed with a mechanical extruder (nozzle size: 0.50 mm) and the PCL shell printed 
with pneumatic extruder (nozzle size: 0.25 mm). Bottom panel: fluorescence microscopy image. 
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previously stated hydrogen bonding and hydrophobic interactions be-
tween DIP and PCL. The resulting DIP-loaded grafts showed a clear 
antithrombotic effect compared with the ones made from PCL without 
the drug. The reduction in the number of deposited platelets to the 
material surface increased by increasing the amount of DIP loaded in the 
grafts. In addition, all the materials prepared in this work were hemo-
compatible and cytocompatible. The obtained results suggest that 3D 
printing can be successfully used for this purpose, and therefore has a 
Fig. 9. Representative stress/strain curves for 3D printed samples (A). Elastic modulus (B), ultimate tensile strength (C) and strain at failure (D) for 3D printed 
samples (n = 4). 
Fig. 10. Rabbit blood hemolysis percentages of the 3D printed vascular grafts, blank PCL (A) and 20% DIP (B). Magnification of the results obtained from the 3D 
printed vascular grafts (C) (n = 4). 
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great potential to be transferred to clinical applications. Moreover, this 
emerging technology allows the manufacture of medical devices on 
demand, with modifications in the shape, size and dose, allowing the 
devices to be personalized/designed to the individual needs of each 
patient. However, there are several aspects that will need to be evalu-
ated prior to use this technology for clinical applications including in 
vivo animal experiments. Moreover, key aspects such as the sterilisation 
of this type of devices need to be evaluated. Conventional techniques 
can be used for this purpose such as gamma irradiation and ethylene 
oxide. However, this will need to be addressed carefully as some steri-
lisation techniques can alter the properties of PCL-based vascular grafts 
[67]. Finally, it is important to note than before any 3D printing tech-
nology can be used for medical device manufacturing regulatory clear-
ance should be obtained. 
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J.C. Montañez, M. Moosazadeh, G. Moradi, M. Moradi, M. Moradi-Lakeh, 
M. Moradinazar, P. Moraga, L. Morawska, I. Moreno Velásquez, J. Morgado-Da- 
Costa, S.D. Morrison, M.M. Moschos, S.M. Mousavi, K.B. Mruts, A.A. Muche, K. 
F. Muchie, U.O. Mueller, O.S. Muhammed, S. Mukhopadhyay, K. Muller, J. 
E. Mumford, G.V.S. Murthy, K.I. Musa, G. Mustafa, A.F. Nabhan, C. Nagata, 
G. Nagel, M. Naghavi, A. Naheed, A. Nahvijou, G. Naik, F. Najafi, H.S. Nam, 
V. Nangia, J.R. Nansseu, N. Neamati, I. Negoi, R.I. Negoi, S. Neupane, C.R. 
J. Newton, J.W. Ngunjiri, A.Q. Nguyen, G. Nguyen, H.T. Nguyen, H.L.T. Nguyen, 
H.T. Nguyen, L.H. Nguyen, M. Nguyen, N.B. Nguyen, S.H. Nguyen, E. Nichols, D.N. 
A. Ningrum, M.R. Nixon, S. Nomura, M. Noroozi, B. Norrving, J.J. Noubiap, H. 
R. Nouri, M.N. Shiadeh, M.R. Nowroozi, E.O. Nsoesie, P.S. Nyasulu, C.M. Odell, 
R. Ofori-Asenso, F.A. Ogbo, I.-H. Oh, O. Oladimeji, A.T. Olagunju, T.O. Olagunju, 
P.R. Olivares, H.E. Olsen, B.O. Olusanya, J.O. Olusanya, K.L. Ong, S.K. Ong, 
E. Oren, A. Ortiz, E. Ota, S.S. Otstavnov, S. Øverland, M.O. Owolabi, M. Pa, 
R. Pacella, A.P. Pakhare, A.H. Pakpour, A. Pana, S. Panda-Jonas, E.-K. Park, J. Park, 
C.D.H. Parry, H. Parsian, Y. Pasdar, S. Patel, S.T. Patil, A. Patle, G.C. Patton, V. 
R. Paturi, D. Paudel, K.R. Paulson, N. Pearce, A. Pereira, D.M. Pereira, N. Perico, 
K. Pesudovs, M. Petzold, H.Q. Pham, M.R. Phillips, D.M. Pigott, J.D. Pillay, M. 
A. Piradov, M. Pirsaheb, F. Pishgar, O. Plana-Ripoll, S. Polinder, S. Popova, M. 
J. Postma, A. Pourshams, H. Poustchi, D. Prabhakaran, S. Prakash, V. Prakash, 
N. Prasad, C.A. Purcell, M. Qorbani, D.A. Quistberg, A. Radfar, A. Rafay, A. Rafiei, 
F. Rahim, K. Rahimi, Z. Rahimi, A. Rahimi-Movaghar, V. Rahimi-Movaghar, 
M. Rahman, M.H.U. Rahman, M.A. Rahman, S.U. Rahman, R.K. Rai, F. Rajati, 
P. Ranjan, P.C. Rao, D. Rasella, D.L. Rawaf, S. Rawaf, K.S. Reddy, R.C. Reiner, M. 
B. Reitsma, G. Remuzzi, A.M.N. Renzaho, S. Resnikoff, S. Rezaei, M.S. Rezai, A.L. 
P. Ribeiro, N.L.S. Roberts, S.R. Robinson, L. Roever, L. Ronfani, G. Roshandel, 
A. Rostami, G.A. Roth, D. Rothenbacher, E. Rubagotti, P.S. Sachdev, N. Sadat, 
E. Sadeghi, S. Saeedi Moghaddam, H. Safari, Y. Safari, R. Safari-Faramani, 
M. Safdarian, S. Safi, S. Safiri, R. Sagar, A. Sahebkar, M.A. Sahraian, H.S. Sajadi, 
N. Salam, J.S. Salama, P. Salamati, Z. Saleem, Y. Salimi, H. Salimzadeh, J. 
A. Salomon, S.S. Salvi, I. Salz, A.M. Samy, J. Sanabria, M.D. Sanchez-Niño, D. 
F. Santomauro, I.S. Santos, J.V. Santos, M.M. Santric Milicevic, B.P. Sao Jose, 
M. Sardana, A.R. Sarker, R. Sarmiento-Suárez, N. Sarrafzadegan, B. Sartorius, 
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